
Expert Insights: how to mitigate risk and be successful in neurodegenerative drug discovery

Research highlights: Targeted Protein Degradation in Tauopathies

Case Study: Development of a human iPSC-derived ALS model
-1.png)
The status of drug discovery and development for Parkinson's disease

Uncovering ALS pathology and potential drug targets with in vitro iPSC models
-1.png)
The status of drug discovery and development for Alzheimer's disease